Cambridge, Mass.-based Glympse Bio Inc. has raised $22 million in a series A financing that's intended to get the company into the clinic in its first couple of indications, as well as to advance it into pharma partnerships. The startup is pursuing a novel approach to diagnostics, as well as treatment and recurrence monitoring, that relies upon an injectable sensor that is activated by disease processes and then becomes detectable in patient urine within about an hour. Read More
